Once-daily dosing of levocabastine has comparable efficacy to twice-daily dosing in the treatment of allergic rhinitis assessed using an allergen challenge chamber

International Journal of Clinical Pharmacology and Therapeutics

Volumn 53, Issue 10, 2015, Pages 811-818

  Murdoch, Robert D ^a   Bareille, Philippe ^a   Ignar, Diane ^b   Mark, Stephen ^c   Miller, Sam R ^a   Gupta, Ashutosh ^d   Salapatek, Anne Marie ^e   Patel, Piyush ^e  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

^c GLAXOSMITHKLINE   (Canada)

^d GlaxoSmithKline Pharmaceuticals Ltd   (India)

^e Inflamax Research   (Canada)

Author keywords

Allergic rhinitis; Levocabastine; Non inferiority; Once daily; Twice daily

Indexed keywords

LEVOCABASTINE; PLACEBO; HISTAMINE H1 RECEPTOR ANTAGONIST; PIPERIDINE DERIVATIVE;

ADULT; AGED; ALLERGIC RHINITIS; ALLERGY TEST; ANXIETY DISORDER; ARTICLE; BACKACHE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NOSE DISEASE; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; SYMPTOM; COMPARATIVE STUDY; DRUG ADMINISTRATION; MIDDLE AGED; PATHOPHYSIOLOGY; RHINITIS, ALLERGIC; YOUNG ADULT;

ADULT; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; MALE; MIDDLE AGED; PIPERIDINES; RHINITIS, ALLERGIC; YOUNG ADULT;

EID: 84946717573     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP202389     Document Type: Article

References (24)

1. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, Zuberbier T, Baena-Cagnani CE, Canonica GW, van Weel C, Agache I, Aït- Khaled N, Bachert C, Blaiss MS, Bonini S, Boulet LP, Bousquet PJ, Camargos P, Carlsen KH, Chen Y, et al; World Health Organization; GA(2)LEN; AllerGen. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008; 63 (Suppl 86): 8-160. CrossRef PubMed
2. Scadding GK, Durham SRR, Mirakian R, Jones NS, Leech SC, Farooque S, Ryan D, Walker SM, Clark AT, Dixon TA, Jolles SR, Siddique N, Cullinan P, Howarth PH, Nasser SM; British Society for Allergy and Clinical Immunology. BSACI guidelines for the management of allergic and non-allergic rhinitis. Clin Exp Allergy. 2008; 38: 19-42. CrossRef PubMed
3. Price D, Bond C, Bouchard J, Costa R, Keenan J, Levy ML, Orru M, Ryan D, Walker S, Watson M. International Primary Care Respiratory Group (IPCRG) guidelines: management of allergic rhinitis. Prim Care Respir J. 2006; 15: 58-70. Cross- Ref PubMed
4. Maurer M, Zuberbier T. Undertreatment of rhinitis symptoms in Europe: findings from a crosssectional questionnaire survey. Allergy. 2007; 62: 1057-1063. CrossRef PubMed
5. Loh CY, Chao SS, Chan YH, Wang DY. A clinical survey on compliance in the treatment of rhinitis using nasal steroids. Allergy. 2004; 59: 1168-1172. CrossRef PubMed
6. Kaliner MA. Azelastine and olopatadine in the treatment of allergic rhinitis. Ann Allergy Asthma Immunol. 2009; 103: 373-380. CrossRef PubMed
7. Canonica GW, Bousquet J, Mullol J, Scadding GK, Virchow JC. A survey of the burden of allergic rhinitis in Europe. Allergy. 2007; 62 (Suppl 85): 17-25. CrossRef PubMed
8. Schatz M. A survey of the burden of allergic rhinitis in the USA. Allergy. 2007; 62 (Suppl 85): 9-16. CrossRef PubMed
9. Navarro A, Valero A, Rosales MJ, Mullol J. Clinical use of oral antihistamines and intranasal corticosteroids in patients with allergic rhinitis. J Investig Allergol Clin Immunol. 2011; 21: 363-369. PubMed
10. Ratner PH, Hampel F, Van Bavel J, Amar NJ, Daftary P, Wheeler W, Sacks H. Combination therapy with azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2008; 100: 74-81. CrossRef PubMed
11. Janssens MM-L, Vanden Bussche G. Levocabastine: an effective topical treatment of allergic rhinoconjunctivitis. Clin Exp Allergy. 1991; 21 (Suppl 2): 29-36. CrossRef PubMed
12. Dechant KL, Goa KL. Levocabastine. A review of its pharmacological properties and therapeutic potential as a topical antihistamine in allergic rhinitis and conjunctivitis. Drugs. 1991; 41: 202-224. CrossRef PubMed
13. Corren J, Rachelefsky G, Spector S, Schanker H, Siegel S, Holton D, Karcher K, Travers S. Onset and duration of action of levocabastine nasal spray in atopic patients under nasal challenge conditions. J Allergy Clin Immunol. 1999; 103: 574-580. CrossRef PubMed
14. Nathan RA, Berger W, Yang W, Cheema A, Silvey M, Wu W, Philpot E. Effect of once-daily fluticasone furoate nasal spray on nasal symptoms in adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2008; 100: 497-505. CrossRef PubMed
15. Fokkens WJ, Jogi R, Reinartz S, Sidorenko I, Sitkauskiene B, van Oene C, Faris MA, Ellsworth A, Caldwell MF. Once daily fluticasone furoate nasal spray is effective in seasonal allergic rhinitis caused by grass pollen. Allergy. 2007; 62: 1078-1084. CrossRef PubMed
16. McCormack PL, Scott LJ. Fluticasone furoate: intranasal use in allergic rhinitis. Drugs. 2007; 67: 1905-1915. CrossRef PubMed
17. Patel P, Holdich T, Fischer von Weikersthal- Drachenberg KJ, Huber B. Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen. J Allergy Clin Immunol. 2014; 133: 121-129.e1-2. CrossRef PubMed
18. European Medicines Agency. Committee for medicinal products for human use (CHMP) - Guideline on the choice of the non-inferiority margin, 2005. http://www.ema.europa.eu/docs/en-GB/ document-library/Scientific-guideline/2009/09/ WC500003636.pdf. Last accessed 19 May 2015.
19. Day JH, Horak F, Briscoe MP, Canonica GW, Fineman SM, Krug N, Leynadier F, Lieberman P, Quirce S, Takenaka H, Cauwenberge P. The role of allergen challenge chambers in the evaluation of anti-allergic medication: an international consensus paper. Clin Exp Allergy Rev. 2006; 6: 31-59. CrossRef
20. Horak F, Stübner UP, Zieglmayer R, Harris AG. Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. J Allergy Clin Immunol. 2002; 109: 956-961. CrossRef PubMed
21. Murdoch RD, Bareille P, Ignar D, Miller S, Gupta A, Boardley R, Zieglmayer P, Zieglmayer R, Lemell P, Horak F. The improved efficacy of a fixed dose combination of fluticasone furoate and levocabastine relative to the individual components in the treatment of allergic rhinitis. Clin Exp Allergy. 2015; DOI 10.1111/cea.12556 [Epub ahead of print]. CrossRef PubMed
22. South Africa Livostin package insert. Revised May 2009 http://www.meppo.com/pdf/drugs/1028-LIVOSTIN- NASAL-SPRAY-1329751247.pdf
23. Mösges R, Spaeth J, Klimek L. Efficacy and tolerability of levocabastine and azelastine nasal sprays for the treatment of allergic rhinitis. Mediators Inflamm. 1995; 4: Sll-S15. PubMed
24. Dymista Package Insert. Last revised 31 October 2013. http://medlibrary.org/lib/rx/meds/dymista/.